

Meeting

# **164th Meeting of the ACNFP 7th February 2024 Agenda**

## **ACNFP/AG/164**

### **Advisory Committee on Novel Foods and Processes**

The 164<sup>th</sup> meeting of the ACNFP will be held as at 10:00am on the 7<sup>th</sup> of February 2024 at Clive House, 70 Petty France, London SW1H 9EX by invite only and on Microsoft Teams (online & dial in).

Members are reminded of the need to announce any commercial interests in the business of the Committee prior to the discussions on each item.

In accordance with agreed procedures, the Secretariat is duty bound to keep a record of the names of Members who have declared interests at meetings of the Committee, giving dates, names of relevant products and companies, details of the interest declared, and whether the Member took part in the proceedings.

ACNFP Secretariat

January 2024

## **164th Meeting of the ACNFP - 7th February 2024 Agenda**

1. Apologies and Announcements
2. Welcome
3. 163rd Meeting Minutes
4. Matters Arising
5. Genetically modified maize and its sub-combinations NX603xT25xDAS-40278-9 RP1791 (reserved business) – The Committee will review the draft safety

assessment outcome developed and agreed by the PGT Subcommittee. ACNFP/164/01

6. Calcidol RP35 - the Committee will review a draft safety assessment outcome. ACNFP/164/02

7. Vitamin D2 mushroom powder RP1550 - the Committee will review the response to the request for further information and a draft safety assessment outcome. ACNFP/164/03

8. Corn protein RP1238 - the Committee will review the response to the request for further information and a draft safety assessment outcome. ACNFP/164/04

9. Regulated Product Service and continuous improvements (reserved business) - the Committee will be updated on planned improvements to the regulated products service and ways of working. ACNFP/164/09

10. CBD - RP350 (reserved business) - the Committee will review a draft safety assessment outcome. ACNFP/164/05

11. CBD - RP427 (reserved business) - the Committee will review a draft safety assessment outcome. ACNFP/164/06

12. CBD - RP07 (reserved business) - the Committee will review a draft safety assessment outcome. ACNFP/164/07

13. Approach to CBD applications where a conclusion on safety cannot be reached (reserved business) - the Committee will consider the proposed approach for applications for CBD as a novel food where there remain significant data gaps. ACNFP/164/08

14. Items for Information

14.1 Update from Novel Foods Policy Team

14.2 Update from GM Policy Team

14.3 SACs update

15. AOB

16. Date of next meeting - 17<sup>th</sup> April 2024